Versican has been found to be co-localised with hyaluronan, CD44 and tenascin in the pericellular matrix in tumours, and because of its ability to interact these modulators of invasion and EGFR (Wu et al, 2005), versican may contribute to the malignant properties of glioma cells. Here, CD44 is linked to central nervous system cancer.